Insights on the Influenza Virus B Infection Drug Market to 2027 | Industry Statistics, Emerging Demands, Forecast to 2027
The global influenza virus B infection drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Influenza viruses cause nose, throat, and sometimes lungs infection. Its symptoms include fever, a cough, sore throat, and body aches. Additionally, type B influenza can cause more severe symptoms than a common cold however, in some cases, there is no need for medical attention. The major factor accelerating the growth of the market is the increasing prevalence of influenza infection across the globe.
Furthermore, the market is also
growing due to new FDA approvals. For instance, in November 2020, Roche
announced the approval of a supplemental New Drug Application (sNDA) for
Xofluza (baloxavir marboxil) from the US Food and Drug Administration (FDA). It
is the first single-dose influenza medicine approved for post-exposure
prophylaxis used as a treatment to prevent influenza in people age 12 years and
older due to coming in contact with someone with influenza.
To Request a Sample of our Report on Influenza Virus B
Infection Drug Market:
https://www.omrglobal.com/request-sample/influenza-virus-b-infection-drug-market
Some major players in the
market include AstraZeneca Plc, F. Hoffmann-La Roche AG, and GlaxoSmithKline
Plc, among others. The market players are contributing significantly to the
growth of the market by the adoption of various strategies including mergers
& acquisitions, geographical expansion, partnerships and collaborations,
and new product launches, to stay competitive in the market. For instance, in
July 2019, Gilead Sciences, Inc. announced that it has received an antiviral
deal with Novartis. The deal was aimed to gain exclusive global rights to
preclinical programmes which involve candidates for the treatment of various
viral infections such as herpes viruses, human rhinovirus and influenza.
Market Coverage
• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
Segment Covered-
•
By Type
•
By Distribution Channel
Regions Covered-
•
North America
•
Europe
•
Asia-Pacific
•
Rest of the World
Competitive Landscape-
AstraZeneca Plc, F. Hoffmann-La Roche AG, and GlaxoSmithKline Plc, among
others.
(Get 15% Discount on Buying this Report)
A
full Report of Influenza Virus B Infection Drug Market is Available @ https://www.omrglobal.com/industry-reports/influenza-virus-b-infection-drug-market
Global Influenza Virus B Infection Drug Market Report by
Segment
By Type
• Peramivir
• Zanamivir
• Oseltamivir Phosphate
• Baloxavir Marboxil
• Others
By Distribution Channel
• Retail Pharmacy
• Hospital Pharmacy
• Others
Global Influenza Virus B Infection Drug Market Report by
Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment